These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753 [TBL] [Abstract][Full Text] [Related]
48. Stromal microenvironment in type VII collagen-deficient skin: The ground for squamous cell carcinoma development. Guerra L; Odorisio T; Zambruno G; Castiglia D Matrix Biol; 2017 Nov; 63():1-10. PubMed ID: 28126522 [TBL] [Abstract][Full Text] [Related]
49. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108 [TBL] [Abstract][Full Text] [Related]
50. Squamous cell carcinoma in a family with dominant dystrophic epidermolysis bullosa: a molecular genetic study. Christiano AM; Crollick J; Pincus S; Uitto J Exp Dermatol; 1999 Apr; 8(2):146-52. PubMed ID: 10232408 [TBL] [Abstract][Full Text] [Related]
53. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines. Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820 [TBL] [Abstract][Full Text] [Related]
54. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Duong T; Wong D; Barrett A; Price H BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637494 [TBL] [Abstract][Full Text] [Related]
55. Verruciform xanthoma in recessive dystrophic epidermolysis bullosa and keratitis-ichthyosis-deafness syndrome: Report of two cases and a review of the literature. Evan-Browning E; Rork J; O'Donnell P; Elaba Z; Deng A; Wiss K Pediatr Dermatol; 2020 Jan; 37(1):176-179. PubMed ID: 31710113 [TBL] [Abstract][Full Text] [Related]
56. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. Fine JD; Johnson LB; Weiner M; Li KP; Suchindran C J Am Acad Dermatol; 2009 Feb; 60(2):203-11. PubMed ID: 19026465 [TBL] [Abstract][Full Text] [Related]
57. Thrombospondin-1 Is a Major Activator of TGF-β Signaling in Recessive Dystrophic Epidermolysis Bullosa Fibroblasts. Atanasova VS; Russell RJ; Webster TG; Cao Q; Agarwal P; Lim YZ; Krishnan S; Fuentes I; Guttmann-Gruber C; McGrath JA; Salas-Alanis JC; Fertala A; South AP J Invest Dermatol; 2019 Jul; 139(7):1497-1505.e5. PubMed ID: 30684555 [TBL] [Abstract][Full Text] [Related]
58. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Bowles DW; Diamond JR; Lam ET; Weekes CD; Astling DP; Anderson RT; Leong S; Gore L; Varella-Garcia M; Vogler BW; Keysar SB; Freas E; Aisner DL; Ren C; Tan AC; Wilhelm F; Maniar M; Eckhardt SG; Messersmith WA; Jimeno A Clin Cancer Res; 2014 Mar; 20(6):1656-65. PubMed ID: 24493827 [TBL] [Abstract][Full Text] [Related]
59. Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa. Ciurescu D; Condruz S; Irimie M Acta Dermatovenerol Alp Pannonica Adriat; 2024 Sep; 33(3):145-149. PubMed ID: 38808531 [TBL] [Abstract][Full Text] [Related]
60. Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma. Ma H; Nie C; Chen Y; Li J; Xie Y; Tang Z; Gao Y; Ai S; Mao Y; Sun Q; Lu R Oncol Res; 2021 Sep; 28(7):745-761. PubMed ID: 33573708 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]